Exicure Announces the Closing of its Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–$XCUR #biotechnology–Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic…